TORONTO, Oct. 6 /CNW/ - Theralase Technologies Inc. (TSX-V: TLT) today
announced that it has delivered a TLC-3000 prototype PDC light system to
University Health Network for the pre-clinical evaluation of Theralase's
patented oxygen independent photodynamic compounds (PDCs) in the destruction
of cancer, bacteria, viruses and fat cells.
The TLC-3000 PDC light system has been specifically designed to increase
the activation of Theralase's PDCs, by optimizing both the wavelength and the
power of the light delivered. The time for activation will now take a tenth of
the time previously required. This significant breakthrough will ultimately
result in a decrease in the treatment time to destroy a given cell type as
well as an increase in the size of cancerous tumours that can be destroyed
with the technology.
"We are pleased to be one step closer to the commercialization of our
PDCs in the destruction of cancer, bacteria, viruses and fat cells," said
Roger Dumoulin-White, President & CEO of Theralase Technologies. "Our unique
platform of patented oxygen independent PDCs have the ability to destroy
cancerous tumours in low oxygen environments that are not able to be destroyed
by any other treatment methodology."
University Health Network demonstrated through trials earlier this year,
that Theralase's patented PDCs have the ability to selectively target and
destroy cancerous cells over cells derived from healthy tissue.
Theralase Technologies Inc. designs, develops and manufactures patented,
super-pulsed laser technology used in a wide range of bio-stimulation and
bio-destruction clinical applications. The Theralase technology platform
targets several diverse healthcare sectors: firstly, for non-invasive pain
management and clinical therapy, in hundreds of neural muscular skeletal
conditions including arthritis; secondly, to bio-stimulate and accelerate
wound care and healing including bone fracture regeneration; and thirdly,
combining photodynamic compounds with super-pulsed, biofeedback laser
technology to attack specifically targeted cancer, bacteria, viruses and fat
cells.
This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation
to update these forward-looking statements.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the contents of this
release.
